Evidence map›Paper›PMID 38755255›Full record

ReviewNPJ precision oncology2024

Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma.

Xin Liu, Hui Shen, Lu Zhang, Wenhui Huang, Shuixing Zhang, Bin Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xin LiuThe First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Hui ShenThe First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Lu ZhangThe First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Wenhui HuangThe First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Shuixing ZhangThe First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China. shui7515@126.com.ORCID http://orcid.org/0000-0001-7377-382X
Bin ZhangThe First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China. xld_Jane_Eyre@126.com.ORCID http://orcid.org/0000-0002-6286-6227

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy, particularly immune checkpoint inhibitors (ICIs), such as anti-programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) therapy, has emerged as a pivotal treatment modality for solid tumors, including recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). Despite the advancements in the utilization of ICIs, there is still room for further improving patient outcomes. Another promising approach to immunotherapy for R/M-NPC involves adoptive cell therapy (ACT), which aims to stimulate systemic anti-tumor immunity. However, individual agent therapies targeting dendritic cells (DCs) appear to still be in the clinical trial phase. This current review underscores the potential of immunotherapy as a valuable adjunct to the treatment paradigm for R/M-NPC patients. Further research is warranted to enhance the efficacy of immunotherapy through the implementation of strategies such as combination therapies and overcoming immune suppression. Additionally, the development of a biomarker-based scoring system is essential for identifying suitable candidates for precision immunotherapy.

Identifiers

PMID38755255
PMCPMC11099100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.